3-May-2024
Pharma R&D productivity seen improving for the first time in years - Deloitte
Seeking Alpha News (Sat, 4-May 3:30 PM ET)
Radiopharma stocks higher as sector welcomes the latest M&A deal
Seeking Alpha News (Thu, 2-May 2:31 PM ET)
Novartis to buy Mariana Oncology for $1B upfront
Seeking Alpha News (Thu, 2-May 7:46 AM ET)
Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
Seeking Alpha News (Tue, 30-Apr 12:18 PM ET)
Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled (update)
Seeking Alpha News (Tue, 30-Apr 11:23 AM ET)
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
Business Wire (Tue, 30-Apr 7:00 AM ET)
Biotech Sector: M&A Fuels Renewed Excitement
TipRanks (Tue, 30-Apr 6:53 AM ET)
Terns Pharmaceuticals releases promising phase 1 data on leukemia candidate
Seeking Alpha News (Mon, 29-Apr 4:31 PM ET)
Terns Pharmaceutical releases promising phase 1 data on leukemia candidate
Seeking Alpha News (Mon, 29-Apr 4:31 PM ET)
Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled
Seeking Alpha News (Mon, 29-Apr 12:47 PM ET)
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of May 3, 2024, NVS stock price declined to $97.27 with 993,278 million shares trading.
NVS has a beta of 0.40, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.07 to the broad based SPY ETF.
NVS has a market cap of $198.47 billion. This is considered a Large Cap stock.
Last quarter Novartis Ag reported $12 billion in Revenue and $1.80 earnings per share. This beat revenue expectation by $349 million and exceeded earnings estimates by $.11.
In the last 3 years, NVS stock traded as high as $108.78 and as low as $74.09.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, FVD, DFAI, GCOW, AVDE.
NVS has underperformed the market in the last year with a price return of -3.3% while the SPY ETF gained +27.0%. NVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.6% and +3.1%, respectively, while the SPY returned +3.7% and +3.3%, respectively.
NVS support price is $96.24 and resistance is $98.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS stock will trade within this expected range on the day.